144 results
Page 3 of 8
424B3
byxab350rcszq26qd33u
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-10.1
5szjuv
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.2
9dtxmm8 49i
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
9ywsvnhtf2v8xij
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
424B5
g94x5 c8pkl1z
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-10.1
lceyc sxkzm
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
n5u9tlan5m1hoxyykt
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm